Nirsevimab for RSV in infants under 1 year
Treatments studied
Part of Infections clinical trials.
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby is younger than 12 months old.
- Baby has a lower respiratory tract infection (like bronchiolitis or pneumonia) confirmed at the hospital.
- Baby has a positive RSV test from a nose swab (for one group).
- Baby is hospitalized for a reason other than a respiratory infection (for the other group).
- No prior treatment with palivizumab (another RSV medicine).
- Mother did not receive an RSV vaccine during pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
This trial looks at how well the drug nirsevimab works for babies hospitalized with RSV bronchiolitis. It also studies the body's immune response and the baby's environment. The goal is to see if nirsevimab can help infants recover from this serious lung infection.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
This study tests if the medicine Nirsevimab can help prevent severe RSV (a common winter virus) in infants in Chile. It is for babies born at specific times in 2023–2024, especially those born early or with health problems.
This trial tests a preventive medicine called nirsevimab given to infants to see how well it protects them from a common serious lung infection. It is offered as part of regular check-ups for babies born during a specific time period.
This study looks at how well the new nirsevimab vaccine works against bronchiolitis in babies. If your infant has their first bout of bronchiolitis and gets a nose swab, they may be able to help researchers understand how the virus spreads and how to better protect other babies.
Hear when a new Respiratory Synctial Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.